'On consolidated basis
Quarter ended June 2025 compared with Quarter ended June 2024.
Net sales (including other operating income) of Lupin has increased 11.93% to Rs 6268.34 crore. Sales of Pharmaceuticals segment has gone up 11.78% to Rs 6,236.41 crore (accounting for 99.49% of total sales). Sales of others segment has gone up 50.98% to Rs 32.28 crore (accounting for 0.51% of total sales).
Profit before interest, tax and other unallocable items (PBIT) has jumped 42.55% to Rs 1,415.54 crore. PBIT of Pharmaceuticals segment rose 41.38% to Rs 1,457.84 crore (accounting for 102.99% of total PBIT). PBIT of others segment fell 11.02% to Rs -42.30 crore (accounting for -2.99% of total PBIT).
PBIT margin of Pharmaceuticals segment rose from 18.48% to 23.38%. PBIT margin of others segment rose from negative 178.20% to negative 131.04%. Overall PBIT margin rose from ...
Pleaselogin & subscribe to view the full report.
More Reports
|
|